KMPH - KemPharm, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.35
-0.05 (-0.78%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.40
Open6.30
Bid6.35 x 900
Ask9.90 x 3200
Day's Range6.30 - 6.50
52 Week Range2.45 - 8.40
Volume51,773
Avg. Volume121,527
Market Cap96.265M
Beta-0.32
PE Ratio (TTM)N/A
EPS (TTM)-2.92
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.92
Trade prices are not sourced from all markets
  • Benzinga4 days ago

    Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst

    KemPharm Inc (NASDAQ: KMPH ) has struggled to gain traction since its 2015 initial public offering, but one long-sidelined analyst is ready for action. The Rating Janney analyst Ken Trbovich initiated ...

  • Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)?
    Simply Wall St.9 days ago

    Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)?

    In this article, I’m going to take a look at KemPharm Inc’s (NASDAQ:KMPH) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • Investopedia16 days ago

    KemPharm Stock Breaks Out on Clinical Trial Results

    KemPharm, Inc. ( KMPH) shares rose more than 10% by Friday afternoon after the company reported positive top-line results from the first of three pivotal human abuse clinical trials for KP415. The prodrug of d-methylphenidate for the treatment of attention deficit and hyperactivity disorder (ADHD) is designed to lower potential abuse compared with stimulant-based ADHD products, which could make it a go-to prescription within the multi-billion-dollar industry. In the clinical trial, researchers found that the prodrug was not readily converted into the active d-methylphenidate when injected, and as a result, it produced pharmacodynamic effects that were comparable to placebo endpoints.

  • Will KemPharm Inc’s (NASDAQ:KMPH) Earnings Grow Over The Next Few Years?
    Simply Wall St.17 days ago

    Will KemPharm Inc’s (NASDAQ:KMPH) Earnings Grow Over The Next Few Years?

    The latest earnings announcement KemPharm Inc’s (NASDAQ:KMPH) released in December 2017 showed that losses became smaller relative to the prrior year’s level – great news for investors Below, I’ve presentedRead More...

  • GlobeNewswire17 days ago

    KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET. Intravenous Human Abuse Potential Trial with KP415 Prodrug Clinical Findings:. Following intravenous ...

  • GlobeNewswire26 days ago

    KemPharm, Inc. to Report First Quarter 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for May 10, 2018, 4:30 p.m. ET. CORALVILLE, Iowa, May 01, 2018-- KemPharm, Inc., a specialty pharmaceutical company focused on the ...

  • ACCESSWIRElast month

    Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

    Stock Monitor: KemPharm Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on VBI Vaccines Inc. (NASDAQ: VBIV ). If you want ...

  • Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH)
    Simply Wall St.2 months ago

    Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH)

    KemPharm Inc’s (NASDAQ:KMPH): KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The US$110.66M market-cap posted a loss in its most recentRead More...

  • GlobeNewswire2 months ago

    KemPharm Reports Fourth Quarter and Year End 2017 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET. FDA Approval Announced of APADAZ™ for the Short-Term Management of Acute Pain on February 23, 2018 Initiated ...

  • ACCESSWIRE2 months ago

    KemPharm, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 29, 2018 / KemPharm, Inc. (NASDAQ: KMPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 29, 2018 at 4:30 PM Eastern Time. To ...

  • GlobeNewswire2 months ago

    KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for March 29th, 2018, 4:30 p.m. ET. CORALVILLE, Iowa, March 21, 2018-- KemPharm, Inc., a specialty pharmaceutical company focused ...

  • GlobeNewswire2 months ago

    KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD

    Results Suggest that Data from Single Classroom-style Efficacy Study May Be Applicable Across Pediatric, Adolescent and Adult ADHD Patient Populations. CORALVILLE, Iowa, March 20, 2018-- KemPharm, Inc., ...

  • GlobeNewswire3 months ago

    KemPharm to Present at Upcoming Investor Conferences

    Presentations to Highlight Corporate and Clinical Progress. CORALVILLE, Iowa, March 06, 2018-- KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary ...

  • At $6, Is KemPharm Inc (NASDAQ:KMPH) A Buy?
    Simply Wall St.3 months ago

    At $6, Is KemPharm Inc (NASDAQ:KMPH) A Buy?

    KemPharm Inc (NASDAQ:KMPH), a pharmaceuticals company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a stock withRead More...

  • Market Exclusive3 months ago

    Here’s What’s Moving KemPharm And Puma Biotechnology

    KemPharm, Inc. (NASDAQ:KMPH) ran into the end of last week on news related to the company’s lead development program. At the close of trade on Friday, KemPharm shares were going for around six dollars apiece, up more than 13% on the day’s open. Premarket on Monday, shares rose again to $6.35 but have since settled […] The post Here’s What’s Moving KemPharm And Puma Biotechnology appeared first on Market Exclusive.

  • Reuters3 months ago

    KemPharm's opioid painkiller gets FDA approval, shares soar

    KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain, sending the shares of the drugmaker up as much as 36 percent in late afternoon trading. The company resubmitted the drug's marketing application for review in September after appealing against a rejection by the drug regulator in 2016 on concerns of opioid abuse. KemPharm said Apadaz is likely to be scheduled as a C-II product - a drug with a high potential for abuse.

  • Reuters3 months ago

    FDA approves KemPharm's opioid painkiller

    KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain. The FDA had said intranasal abuse of the opioid-based product was a relevant concern. KemPharm said the Drug Enforcement Administration (DEA) intends to schedule Apadaz as a C-II product.

  • Why KemPharm Inc’s (NASDAQ:KMPH) CEO Salary Matters To You
    Simply Wall St.3 months ago

    Why KemPharm Inc’s (NASDAQ:KMPH) CEO Salary Matters To You

    Travis Mickle took the reins as CEO of KemPharm Inc’s (NASDAQ:KMPH) and grew market cap to US$84.99M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • ACCESSWIRE4 months ago

    Blog Exposure - KemPharm Announces Patent Grant for KP606 and KP511-Related Family

    LONDON, UK / ACCESSWIRE / January 25, 2018 / Active-Investors.com has just released a free research report on KemPharm, Inc. (NASDAQ: KMPH ). If you want access to this report all you need to do is sign ...

  • Should You Be Concerned About KemPharm Inc’s (undefined:KMPH) Investors?
    Simply Wall St.5 months ago

    Should You Be Concerned About KemPharm Inc’s (undefined:KMPH) Investors?

    Today, I will be analyzing KemPharm Inc’s (NASDAQ:KMPH) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects both its short-Read More...